Ridgeback Biotherapeutics

Ridgeback Biotherapeutics is a biotechnology company focused on developing therapeutics for infectious diseases. Founded in 2015, the company gained significant prominence for its rapid development of a treatment for COVID-19 during the global pandemic. Its pipeline primarily targets RNA viruses, including Ebola and Marburg, leveraging expertise in monoclonal antibody discovery and development.

History and founding

The company was established in 2015 by Wendy Holman and Wayne Holman, a husband-and-wife team with backgrounds in finance and medicine. Initial operations were based in Miami, Florida, with a strategic focus on overlooked and emerging viral threats. Early work centered on advancing a therapeutic candidate for Ebola virus disease, building upon research from institutions like the University of Texas Medical Branch and the National Institutes of Health. The firm's trajectory shifted dramatically with the onset of the COVID-19 pandemic, prompting a swift pivot to address the novel SARS-CoV-2 virus. This effort was catalyzed by a licensing agreement with Vanderbilt University Medical Center for a promising monoclonal antibody candidate.

Key products and development

The company's most notable product is molnupiravir, an oral antiviral drug developed for the treatment of COVID-19. Originally investigated at Emory University for Venezuelan equine encephalitis virus, the compound was licensed from Emory University and Merck in 2020. Another significant asset is Ansuvimab (also known as mAb114), a monoclonal antibody for Ebola virus disease developed in collaboration with the National Institute of Allergy and Infectious Diseases and the Democratic Republic of the Congo. The pipeline also includes preclinical candidates targeting Marburg virus and other tropical disease pathogens, reflecting a continued commitment to neglected tropical diseases and global health security.

Collaborations and partnerships

Strategic alliances have been central to its development model. A pivotal partnership with Merck & Co. was formed in 2020 to co-develop and commercialize molnupiravir, leveraging Merck's global manufacturing and regulatory capabilities. The company has also maintained a longstanding collaboration with the National Institutes of Health, particularly the National Institute of Allergy and Infectious Diseases led by Anthony Fauci, on Ebola therapeutics. Key academic partnerships include licenses with Vanderbilt University Medical Center for SARS-CoV-2 antibodies and with the University of Texas Medical Branch for Marburg virus research. Additional funding and support have come from organizations like the Biomedical Advanced Research and Development Authority and the World Health Organization.

Clinical trials and regulatory status

Molnupiravir was evaluated in the pivotal MOVe-OUT trial, a global Phase III study that demonstrated reduced risk of hospitalization in non-hospitalized adults with COVID-19. This data led to an Emergency Use Authorization from the U.S. Food and Drug Administration in December 2021 and conditional marketing authorization from the European Medicines Agency. For Ebola, Ansuvimab was studied in the PALM trial conducted by the World Health Organization and the National Institute of Allergy and Infectious Diseases in the Democratic Republic of the Congo, leading to its approval by the U.S. Food and Drug Administration in 2020. Ongoing clinical investigations include studies on Marburg virus treatments and next-generation COVID-19 therapeutics.

Corporate structure and leadership

The firm operates as a privately held entity headquartered in Miami, Florida. Wendy Holman serves as the Chief Executive Officer, while Wayne Holman acts as Chairman of the board. The leadership team includes veterans from the pharmaceutical industry and academic research, guiding strategy and operations. Its development and commercial activities for molnupiravir are conducted in partnership with Merck & Co., which handles large-scale manufacturing and distribution under the brand name Lagevrio. The company maintains a lean operational model, focusing on research, early development, and strategic alliances while leveraging partners for later-stage trials and global commercialization.

Category:Biotechnology companies of the United States Category:Pharmaceutical companies established in 2015 Category:Companies based in Miami